American College of Clinical Pharmacy
      Search      Cart
         
ACCP Report

Washington Report

Health Care Advocacy and the Pandemic: New Normal?

Written by John McGlew
Director of Government Affairs


Capitol

When the COVID-19 pandemic first swept across the country in early March, ACCP’s advocacy priorities pivoted to focus on positioning the profession of clinical pharmacy to fully and appropriately participate in the pandemic response effort. Throughout this effort, the College and its members have worked collaboratively with partner organizations within and beyond the pharmacy profession in calling for a coordinated, science-based pandemic response that does not compromise on established process-of-care protocols or personal safety standards.

Advocacy Programming at the virtual 2020 ACCP Annual Meeting

To learn more about ACCP’s advocacy work during the COVID-19 crisis, attend the following virtual learning session:

Facing the Future: Advancing the Evolving Payment and Policy Models Beyond COVID

(Tuesday, October 27, from 2:30 p.m. to 4:00 p.m. [CDT]; available for 1.5 hours of CPE credit)

COVID-19 and the Substance Abuse Disorder Epidemic

Even before COVID-19, the nation’s health delivery infrastructure faced complex challenges, which have since been exacerbated by the pandemic. The long-term sustainability of medical practices – long thought of as an issue specific to Medicare “entitlement spending” – has reached crisis levels as primary care practices struggle to adapt to a reality in which revenues from fee-for-service, episodic care have collapsed. ACCP has worked hard over the years to build strong relationships with its colleagues in organized medicine. As a result, the College believes the profession has an opportunity to advance medication optimization through comprehensive medication management (CMM) as a solution to struggling physician practices by helping to advance the transition to integrated, collaborative care and outcomes-based payment structures.

The nation’s ongoing opioid and substance abuse disorder (SUD) epidemic, which claimed over 70,000 lives in 2019, is projected to worsen as the psychological effect of isolation takes its toll. In August, recognizing this mounting crisis, bipartisan leaders from the House Committee on Energy and Commerce wrote to Health and Human Services Secretary Alex Azar to request an updated briefing on the latest trends in substance use and overdoses, how these trends are affected by the COVID-19 pandemic, and what more the federal government needs to do to address this growing crisis.

As part of this advocacy process, ACCP wrote to congressional leaders to recommend an interprofessional approach to SUD management, and management of acute and chronic pain, by integrating clinical pharmacists into the care team. Click here to read ACCP’s statement in full.

Opioid and Substance Abuse Programming at the virtual 2020 ACCP Annual Meeting

Join us for an exciting virtual session:

Team-Based Management of Opioid Misuse Across the Care Continuum
(Tuesday, October 27, from 11:00 a.m. to 12:30 p.m. [CDT]; available for 1.5 hours of CPE credit)